Trial Profile
Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma; Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Paclitaxel trevatide (Primary)
- Indications Anaplastic astrocytoma; Brain metastases; Meningeal carcinomatosis; Oligodendroglioma
- Focus Expanded access; Therapeutic Use
- Sponsors AngioChem
- 03 Jun 2016 Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis is now added. Thus changes in Scientific title, purpose and indication.
- 05 May 2016 New trial record